Efficacy and Safety of Tran Cannula in Combined Pseudoexfoliative Glaucoma and Cataract Surgery Compared With Augmented Ocular Irrigation

February 5, 2026 updated by: Hôpital Privé de la Baie

Pseudoexfoliative glaucoma is a glaucoma secondary to pseudoexfoliative syndrome; cataract surgery is often more difficult, with more complications. Tran's cannula is a single-use irrigation system designed for cleaning, with the pseudoexfoliative material remaining in the trabecular meshwork.

The main objective of this study is to evaluate the efficacy of the Tran cannula, in comparison with increased irrigation, in lowering intraocular pressure (IOP) in patients with pseudoexfoliative glaucoma and treated for glaucoma, and with an indication for isolated cataract surgery.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

58

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Avranches, France
        • Recruiting
        • Hôpital Privé de la Baie
      • Paris, France
      • St-Malo, France, 35400
        • Not yet recruiting
        • Clinique de la Côte d'Emeraude
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients with cataract and early-to-moderate pseudoexfoliative glaucoma (GPX) scheduled for isolated cataract surgery.
  • Reliable visual field, Humphrey 24-2, Sita-Fast, with typical glaucoma alterations, and with mean deviation ≤-12 dB.
  • OCT with ganglion cell alterations and fibers typical of glaucoma.
  • Typical glaucomatous neuropathy
  • Slit-lamp signs of pseudoexfoliation.
  • Open angle (2 to 4, according to Shaffer classification) determined by gonioscopy.
  • Untreated eye pressure >21 mmHg and <33 mmHg

Exclusion Criteria:

  • Presence of other ophthalmological pathologies (except cataract or mild dry eye)
  • History of intraocular surgery in the last 12 months, history of trauma
  • History of laser trabeculoplasty (TLA or SLT) in the previous 12 months
  • Visual acuity below "finger count
  • Myopia ≥ 6 dioptres, hyperopia ≥ 5 dioptres
  • Iridocorneal angle closure (and angle-closure glaucoma), any other type of non-pseudoexfoliative glaucoma, iris neovascularization
  • Pachymetry < 490 μm or > 620 μm; or corneal pathology or other condition that makes accurate IOP measurements with flattening tonometry, ultrasonic pachymetry or specular microscopy impossible.
  • Presence of severe systemic pathologies

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Tran cannula surgery
Patients treated with Tran cannula
Procedure: Tran canula
After phacoemulsification, implantation of the intraocular implant and aspiration of the viscoelastic, we connect the TranCanula® to the irrigation system. Then we treat the trabecular mesh.
Active Comparator: augmented irrigation surgery
Patients treated with augmented irrigation cannula.
Procedure: augmented irrigation
After phacoemulsification, We use the classical aspiration cannula to irrigate the trabecular mesh.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Intraocular pressure measure
Time Frame: day 1, day 30, month 3, month 6 and month 12 after surgery
day 1, day 30, month 3, month 6 and month 12 after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hôpital Privé de la Baie

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 4, 2025

Primary Completion (Estimated)

February 2, 2028

Study Completion (Estimated)

February 2, 2029

Study Registration Dates

First Submitted

May 12, 2025

First Submitted That Met QC Criteria

May 12, 2025

First Posted (Actual)

May 20, 2025

Study Record Updates

Last Update Posted (Actual)

February 6, 2026

Last Update Submitted That Met QC Criteria

February 5, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2023-23-PDB

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cataract

Clinical Trials on Tran canula

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe